@celinehalioua notes Her2 is the obvious example here.
-
-
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi
-
-
-
Agios with their IDH inhibitors
-
Great example!
Kraj razgovora
Novi razgovor -
-
-
Agios and Sage
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi
-
-
-
Is that the right question? Usually doesn’t make sense for a company to build a sales force when they could just be acquired by another company that already has a sales and marketing engine.
-
of course it's the right question. tech VCs want to make their name is biotech and keep ignoring the obvious benchmark they'd have to beat or at least emulate. BTW, no AI was required in Agios's case. You could also argue that the Vertex CF triple combo qualifies, too
- Još 1 odgovor
Novi razgovor -
-
-
@RecursionChris out of my depth here, but is this your goal with Recursion? Didn’t realize it’s that rare to take a therapy all the way from target discovery to market.Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi
-
-
-
I think Incyte with Jak inhibitor
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi
-
-
-
What does an internally developed target mean? We know all the proteins in the human genome, for example. Do you mean a target as in a hypothesis for disease? If so, isn’t that what all forms of drug dev do to some extent?
-
If you mean a binding cleft on a known protein, isn’t this what all GPCR drug discovery does for instance?
Kraj razgovora
Novi razgovor -
Čini se da učitavanje traje već neko vrijeme.
Twitter je možda preopterećen ili ima kratkotrajnih poteškoća u radu. Pokušajte ponovno ili potražite dodatne informacije u odjeljku Status Twittera.